{"title":"Cervical cancer stage distribution and survival outcomes in Africa: a systematic review and meta-analysis.","authors":"Chidinma Anakwenze, Anjali Kalra, Christian Lumley, Ganen Chinniah, Mark Munsell, Thriaksh Rajan, Gauthami Moorkanat, Priyanka Mehta, Agnes Ewongwo, Luca Valle, Katie Lichter, Yimin Geng, Surbhi Grover","doi":"10.1016/j.ijgc.2024.100008","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Cervical cancer is a leading cause of cancer-related deaths among women, with a disproportionate burden in sub-Saharan Africa. Understanding the cervical cancer stage and outcomes is crucial for developing effective interventions and reducing its burden. We aimed to undertake a systematic review and meta-analysis of cervical cancer stage distribution and survival outcomes in Africa.</p><p><strong>Methods: </strong>We searched MEDLINE, Embase, PubMed, Cochrane Library, Clarivate Analytics Web of Science, and the World Health Organization African Index Medicus database for publications in all languages from the inception of databases to July 2021. A total of 144 studies published between 1978 and 2021 from 33 African countries were included, encompassing 55,747 patients.</p><p><strong>Results: </strong>We revealed that 53.3% (95% CI 50.9 to 55.6) of cervical cancer cases in Africa were diagnosed at late stages (stage III-IV). This proportion varied significantly across countries and regions, ranging from 7.7% to 86.3%. The study also highlighted disparities by Human Development Index (HDI) grouping, with low HDI countries exhibiting higher proportions of late-stage diagnoses (56.0%, 95% CI 51.6 to 60.4) compared with medium (51.2%, 95% CI 47.5 to 54.9) and high (50.7%, 95% CI 47.0 to 54.5) HDI countries. Notably, there was no stage migration observed over time (p = .53). The median overall survival was 24.0 months (interquartile range, 19.2-39.4).</p><p><strong>Conclusion: </strong>These stage and outcomes data highlight the need for expanding cervical cancer screening and treatment and are crucial for policymakers to develop evidence-based strategies aimed at accelerating the elimination of cervical cancer in Africa. Additionally, standardized data collection and reporting are needed to facilitate better monitoring of cervical cancer outcomes across countries.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 1","pages":"100008"},"PeriodicalIF":4.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecological Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijgc.2024.100008","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Cervical cancer is a leading cause of cancer-related deaths among women, with a disproportionate burden in sub-Saharan Africa. Understanding the cervical cancer stage and outcomes is crucial for developing effective interventions and reducing its burden. We aimed to undertake a systematic review and meta-analysis of cervical cancer stage distribution and survival outcomes in Africa.
Methods: We searched MEDLINE, Embase, PubMed, Cochrane Library, Clarivate Analytics Web of Science, and the World Health Organization African Index Medicus database for publications in all languages from the inception of databases to July 2021. A total of 144 studies published between 1978 and 2021 from 33 African countries were included, encompassing 55,747 patients.
Results: We revealed that 53.3% (95% CI 50.9 to 55.6) of cervical cancer cases in Africa were diagnosed at late stages (stage III-IV). This proportion varied significantly across countries and regions, ranging from 7.7% to 86.3%. The study also highlighted disparities by Human Development Index (HDI) grouping, with low HDI countries exhibiting higher proportions of late-stage diagnoses (56.0%, 95% CI 51.6 to 60.4) compared with medium (51.2%, 95% CI 47.5 to 54.9) and high (50.7%, 95% CI 47.0 to 54.5) HDI countries. Notably, there was no stage migration observed over time (p = .53). The median overall survival was 24.0 months (interquartile range, 19.2-39.4).
Conclusion: These stage and outcomes data highlight the need for expanding cervical cancer screening and treatment and are crucial for policymakers to develop evidence-based strategies aimed at accelerating the elimination of cervical cancer in Africa. Additionally, standardized data collection and reporting are needed to facilitate better monitoring of cervical cancer outcomes across countries.
目标:子宫颈癌是妇女癌症相关死亡的主要原因,在撒哈拉以南非洲造成了不成比例的负担。了解子宫颈癌的阶段和结果对于制定有效的干预措施和减轻其负担至关重要。我们的目的是对非洲宫颈癌分期分布和生存结果进行系统回顾和荟萃分析。方法:我们检索MEDLINE、Embase、PubMed、Cochrane Library、Clarivate Analytics Web of Science和World Health Organization African Index Medicus数据库,检索从数据库建立到2021年7月所有语言的出版物。从1978年到2021年,共纳入了来自33个非洲国家的144项研究,涉及55,747名患者。结果:我们发现53.3% (95% CI 50.9至55.6)的非洲宫颈癌病例被诊断为晚期(III-IV期)。这一比例在不同国家和地区差异很大,从7.7%到86.3%不等。该研究还强调了人类发展指数(HDI)分组的差异,低HDI国家的晚期诊断比例(56.0%,95% CI 51.6至60.4)高于中HDI国家(51.2%,95% CI 47.5至54.9)和高HDI国家(50.7%,95% CI 47.0至54.5)。值得注意的是,随着时间的推移,没有观察到阶段性迁移(p = .53)。中位总生存期为24.0个月(四分位数间距为19.2-39.4)。结论:这些阶段和结果数据强调了扩大宫颈癌筛查和治疗的必要性,对于决策者制定旨在加速消除非洲宫颈癌的循证战略至关重要。此外,需要标准化的数据收集和报告,以便更好地监测各国的宫颈癌结果。
期刊介绍:
The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.